Vitrolife
Vitrolife AB is a Swedish medical technology company focused on developing, manufacturing, and marketing products for in vitro fertilization treatment. The company produces nutrient culture media, disposable surgical needles, embryo transfer catheters, micro-pipettes, time-lapse incubation systems, and genetic testing solutions for assisted reproduction. Primary revenue streams are derived from the sale of IVF media, disposable medical devices, capital equipment for embryology labs, and reproductive genetic testing services. Vitrolife serves fertility clinics, reproductive health centers, public and private hospitals, and clinical IVF specialists globally. The enterprise holds a leading international market position in culture media and embryo incubation equipment for reproductive medicine. Vitrolife AB is headquartered in Gothenburg, Sweden, and its common shares are listed on Nasdaq Stockholm.
23 of the funds FundTelligence covers report a position in Vitrolife.
- Legal name
- Vitrolife AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 23
- Exposure themes
- Reproductive health, Treatment, Women's Health
Funds holding Vitrolife
- Ruth Core Nordic Small Cap — Ruth · 2.9 % (largest positions only, September 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 1.83 % (full portfolio disclosed, June 2026)
- Cliens Small & Micro Cap — Cliens · 1.46 % (full portfolio disclosed, June 2026)
- DNB Fund Women's Health — DNB · 1.27 % (full portfolio disclosed, August 2026)
- DNB Fund Nordic Small Cap — DNB · 1.04 % (full portfolio disclosed, September 2026)
- Vibrand Norden — Vibrand · 0.92 % (full portfolio disclosed, June 2026)
- Lannebo Sweden Micro Cap — Lannebo · 0.57 % (full portfolio disclosed, June 2026)
- Nordea Alfa — Nordea Funds · 0.57 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 23 funds holding it.